{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:59:53Z","timestamp":1776722393951,"version":"3.51.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>We report a case of a 33-year-old male with ankylosing spondylitis (AS) who had been receiving secukinumab (150 mg monthly) for 2 years. Approximately 1 year after initiating treatment, the patient developed recurrent, multiple sterile pustules on the palms and soles. Various topical treatments, including corticosteroids and calcipotriol, yielded minimal improvement. 1 week prior to presentation, new pustular lesions emerged on the trunk and extremities, accompanied by pruritus followed by burning sensations and tenderness. Histopathological examination revealed subcorneal pustule formation within the epidermis and sparse lymphocytic infiltration in the dermis. A diagnosis of secukinumab-induced pustular reaction was made. Following the discontinuation of secukinumab and the initiation of upadacitinib (15 mg\/day) for over 1 month, the pustules largely resolved, and symptoms were significantly alleviated. This case suggests that IL-17A inhibitors may trigger pustular cutaneous reactions in AS patients. Clinicians should remain vigilant regarding such adverse effects and adjust treatment regimens promptly. JAK inhibitors may provide an effective therapeutic option for managing these drug-induced reactions.<\/jats:p>","DOI":"10.3389\/fmed.2026.1786722","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:26:04Z","timestamp":1773379564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Secukinumab induced pustular eruption in a patient with ankylosing spondylitis"],"prefix":"10.3389","volume":"13","author":[{"given":"Zenan","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101670","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.mcna.2024.02.004","article-title":"Newer therapies in rheumatology","volume":"108","author":"Bays","year":"2024","journal-title":"Med Clin North Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/cpt.3464","article-title":"Model-informed drug development-based approval of intravenous secukinumab for the treatment of adult patients with active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis","volume":"117","author":"Pisal","year":"2025","journal-title":"Clin Pharmacol Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12016-025-09042-5","article-title":"The role of IL-17 in systemic autoinflammatory diseases: mechanisms and therapeutic perspectives","volume":"68","author":"Zhang","year":"2025","journal-title":"Clin Rev Allergy Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1364127","DOI":"10.3389\/fmed.2024.1364127","article-title":"Paradoxical reaction to IL-17A inhibitor: a case report and literature review","volume":"11","author":"Ren","year":"2024","journal-title":"Front Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1093\/rheumatology\/kead318","article-title":"The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study","volume":"62","author":"Yagiz","year":"2023","journal-title":"Rheumatology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e50726","DOI":"10.7759\/cureus.50726","article-title":"Paradoxical psoriasis and worsening spondylitis due to secukinumab in a patient with ankylosing spondylitis: a case report and literature review","volume":"15","author":"Alnaqbi","year":"2023","journal-title":"Cureus."},{"key":"B11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/bjd\/ljac024","article-title":"Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry","volume":"188","author":"Aubert","year":"2023","journal-title":"Br J Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e70122","DOI":"10.1111\/exd.70122","article-title":"Extension of secukinumab and ixekizumab dose for moderate-to-severe psoriasis in low disease activity intervals","volume":"34","author":"Wang","year":"2025","journal-title":"Exp Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/ced\/llaf250","article-title":"Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and brodalumab for up to 1 year after dose spacing","volume":"50","author":"Mastorino","year":"2025","journal-title":"Clin Exp Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/ijd.16915","article-title":"Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting","volume":"63","author":"Daud\u00e9n","year":"2024","journal-title":"Int J Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.5826\/dpc.1503a5845","article-title":"Impact of disease activity-guided dose reduction on IL-17 and IL-23 inhibitors in psoriasis: a real-world assessment of efficacy, safety, and economic benefits","volume":"15","author":"Cammarata","year":"2025","journal-title":"Dermatol Pract Concept"},{"key":"B16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/bioengineering9080387","article-title":"Long-term dose optimization of adalimumab via dose spacing in patients with psoriasis","volume":"9","author":"Benzaquen","year":"2022","journal-title":"Bioengineering"},{"key":"B17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","article-title":"Treatment of axial spondyloarthritis: an update","volume":"18","author":"Danve","year":"2022","journal-title":"Nat Rev Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1226528","DOI":"10.3389\/fphar.2023.1226528","article-title":"Comparison of biologics and small-molecule drugs in axial spondyloarthritis: a systematic review and network meta-analysis","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.jaad.2011.05.038","article-title":"Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-\u03b1 inhibitors: the Mayo Clinic experience, 1998 to 2010","volume":"67","author":"Shmidt","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jaci.2023.06.004","article-title":"Successful treatment of JAK1-associated inflammatory disease","volume":"152","author":"Fayand","year":"2023","journal-title":"J Allergy Clin Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25259\/IJDVL_29_2023","article-title":"Janus kinase inhibitors for the treatment of psoriatic arthritis","volume":"11","author":"Raychaudhuri","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2594352","DOI":"10.1080\/07853890.2025.2594352","article-title":"Targeting the JAK\/STAT pathway in palmoplantar pustulosis: a review","volume":"57","author":"Vimbai Chirindo","year":"2025","journal-title":"Ann Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1786722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:26:04Z","timestamp":1773379564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1786722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":22,"alternative-id":["10.3389\/fmed.2026.1786722"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1786722","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1786722"}}